STLX 1018
Alternative Names: STLX-1018Latest Information Update: 03 Feb 2023
At a glance
- Originator Stelexis Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 17 Jan 2023 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) (Stelexis Therapeutics pipeline; January 2023)
- 17 Jan 2023 Stelexis Therapeutics plans to submit IND application for STLX 1018 in Acute myeloid leukemia (Stelexis Therapeutics pipeline; January 2023)
- 17 Jan 2023 Stelexis Therapeutics plans a clinical trial for STLX 1018 in Acute myeloid leukemia (Stelexis Therapeutics pipeline; January 2023)